Back to Search Start Over

Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting.

Authors :
Herta, Toni
Joachim‐Richter, Anna
Petroff, David
Wölk, Benno
Wolffram, Ingmar
Berg, Thomas
Kramer, Jan
Bätz, Olaf
Wiegand, Johannes
Source :
Alimentary Pharmacology & Therapeutics. Dec2024, p1. 7p. 2 Illustrations.
Publication Year :
2024

Abstract

ABSTRACT Background Aims Methods Results Conclusions Trial Registration Despite European guidelines recommending anti‐hepatitis D virus (HDV) screening for all hepatitis B surface antigen (HBsAg)‐positive cases, screening rates remain insufficient.We analysed anti‐HDV screening rates in primary care and implemented prospective HDV screening in HBsAg‐positive cases identified in the preventive medical examination from the age of 35 (“Check‐Up 35+”).From 2012 to 2021, we reviewed anti‐HDV and HDV RNA test rates in HBsAg‐positive patients at 11 sites of a large German laboratory group. From 2022 to 2023, we prospectively screened HBsAg‐positive samples from the “Check‐Up 35+” for anti‐HDV. Anti‐HDV positive patients were then contacted again for HDV RNA testing.Retrospectively, 2792/13,905 (20%) HBsAg‐positive cases were tested for anti‐HDV, with 142/2792 (5.1%) being positive. HDV RNA was tested in 57/142 (40%) anti‐HDV‐positive cases, with 26/57 (46%) being positive. In the prospective screening, 1159/225,901 (0.51%) individuals were HBsAg‐positive. Of these, 700 (60%) were tested for anti‐HDV, with 18/700 (2.6%) positive test results. 4/18 (22%) were successfully contacted again for HDV RNA analysis, with one case testing positive. Neither the HBsAg nor the anti‐HDV positive result was known prior to screening in these cases. Anti‐HDV testing could not be performed in 459/1159 (40%) HBsAg‐positive cases, primarily due to insufficient blood sample volume (310/459 cases, 68%), with others missed due to logistical errors.Retrospective data show insufficient anti‐HDV screening in clinical routine. The prospective anti‐HDV screening provides a blueprint for using existing hepatitis B virus screening programms for population‐based HDV double reflex testing, provided that adequate logistical prerequisites are established.German Clinical Trial Register: DRKS00029180 [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02692813
Database :
Academic Search Index
Journal :
Alimentary Pharmacology & Therapeutics
Publication Type :
Academic Journal
Accession number :
181274226
Full Text :
https://doi.org/10.1111/apt.18424